@GD, are they really legally allowed to sit on the data for weeks just because it's not 'great data'? I guess maybe they could, because they could simply say the analysis isn't finished. I've no idea on that level of fancy footwork with this stuff.
I doubt he would discuss the result with anyone before the data is sent to the FDA. He was quoted on saying, first the FDA, shareholders next and he is bound by the constraints of SEC filings (i.e. material information....has to be revealed 2 days after receiving it)
2. Timeliness The listed entity shall disclose ongoing information on a timely basis, which could require disclosure on an: (a) immediate basis for disclosure of material developments, where such a term could be defined as “as soon as possible” or prescribed as a maximum of specified days (such as 2 business days, as proposed in the USA); and